naltrexone hydrochloride tablet, film coated
tagi pharma inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets usp are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone hydrochloride is a pure opioid antagonist. it does not
naltrexone hydrochloride tablet, film coated
physicians total care, inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone or laam (levo-alpha-acetyl-methadol). - patients in acute opioid withdrawal (see warnings). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. - any individual with acute hepatitis or liver failure. naltrexone is a pure opioid antagonist. it does not lead to physical or psyc
naltrexone hydrochloride tablet, film coated
accord healthcare, inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets usp 50 mg is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp 50 mg has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone ) or partial agonists (e.g., buprenorphine) - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product.it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone hydrochloride is a pure opioid antagonist. it does not lead to physical or psychological dependence. tolerance to the opioid antagonist effect is not known to occur.
naltrexone hydrochloride tablet, film coated
american health packaging - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). - patients in acute opioid withdrawal ( see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone is a pure opioid antagonist. it does not lead to physical or psychological dependence.
naltrexone hydrochloride tablet, film coated
bryant ranch prepack - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets usp 50 mg is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp 50 mg has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone ) or partial agonists (e.g., buprenorphine) - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product.it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone hydrochloride is a pure opioid
naltrexone hydrochloride- naltrexone hydrochloride tablet, film coated
preferred pharmaceuticals inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets usp 50 mg is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp 50 mg has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in naltrexone hydrochloride is a pure opioid antagonist. it does not lead to physical or psychological dependence. tolerance to the opioid antagonist effect is not known to occur.
naltrexone hydrochloride tablet, film coated
h.j. harkins company inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets usp are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in: patients receiving opioid analgesics. patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). patients in acute opioid withdrawal (see warnings). any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone hydrochloride is a pure opioid antagonist. it
naltrexone 50mg tablets
aop orphan ltd - naltrexone hydrochloride - oral tablet - 50mg
holoxan 2g powder for injection vial
baxter healthcare pty ltd - ifosfamide, quantity: 2 g - injection, powder for - excipient ingredients: - use in the treatment of tumours sensitive to ifosfamide either as a single agent or in combination with other chemotherapeutic agents. tumour types that have been demonstrated to respond to ifosfamide single agent or in combination are germ cell tumours, sarcomas, lymphomas. anti-tumour activity has been shown in ovarian and cervical cancers. some activity has also been seen in lung and breast cancer.
holoxan 1g powder for injection vial
baxter healthcare pty ltd - ifosfamide, quantity: 1 g - injection, powder for - excipient ingredients: - use in the treatment of tumours sensitive to ifosfamide either as a single agent or in combination with other chemotherapeutic agents. tumour types that have been demonstrated to respond to ifosfamide single agent or in combination are germ cell tumours, sarcomas, lymphomas. anti-tumour activity has been shown in ovarian and cervical cancers. some activity has also been seen in lung and breast cancer.